To promote truly personalized medicine and medical care, the Icahn School of Medicine at Mount Sinai (ISSM) and the Rensselaer Polytechnic Institute (RPI) are collaborating on educational programs, research, and the development and commercialization of new diagnostic tools and treatments that promote human health and drive down health care costs. ISSM recently launched a new partnership webpage with information on the partnership and on upcoming events.
The partnership established between Rensselaer Polytechnic Institute and Mt. Sinai is supported as part of a $100 million public-private initiative to boost biotechnology innovation in New York, administered through Mount Sinai Innovations Partners (MSIP – formerly known as the Office of Technology & Business Development). The goal of the partnership is to serve the larger community by facilitating the transfer of medical discovery from the laboratory to the marketplace.
Rensselaer Polytechnic Institute announced the partnership with Mount Sinai in early 2013. MSIT seeks to transform biomedicine through discovery and development of technology-based solutions to critical unmet health-care needs. Students and faculty will engage in academic research, product development, and active entrepreneurship in areas including Big Data, cloud computing, social networking, scientific and clinical simulation, tissue engineering, sensors, microprocessors, robotics, mechatronics, drug delivery and nanomedicine, and other areas, ultimately conferring graduate degrees in Design, Technology, and Entrepreneurship (Ph.D.) and Biomedical Informatics (M.S.).
As part of the MSIT program, which will begin this fall, Rensselaer and Mount Sinai will collaborate on the creation of seven multidisciplinary research teams. Comprised of faculty members, post-doctoral scholars, and students from both institutions, each team will be devoted to solving a specific technology problem.
This collaboration furthers the partnership between Rensselaer and Mount Sinai, which announced in May 2013 an affiliation agreement to collaborate on educational programs, research, and development of new diagnostic tools and treatments that promote human health. The affiliation leverages the expertise of Rensselaer in engineering and invention prototyping and the expertise of Mount Sinai in biomedical research and patient care to develop joint educational programs, create complementary research programs, and to seek joint research funding.
Accelerating Research Results
The affiliation expands the research conducted at both institutions in the areas of neuroscience and neurological diseases, genomics, imaging, orthopaedics, cancer, cardiovascular disease, and scientific and clinical targets. Funding for projects will be sought on topics including precision medicine, drug discovery, stem cell biology, robotics and robotic surgery, novel imaging techniques, cellular engineering, and computational neurobiology.
“The Mount Sinai Institute of Technology is a robust extension of our partnership with the Icahn School of Medicine,” said Rensselaer President Shirley Ann Jackson. “This research and technology hub will enable innovation and discovery in biomedical technologies, health-care analytics, and education, and will drive economic development and improved health care. Rensselaer will work closely with Mount Sinai to foster the growth of the MSIT, while expanding opportunities to build Rensselaer-driven biomedical technologies upstate.”
“We are grateful to the New York City Economic Development Corporation and the administration of Mayor Michael R. Bloomberg for their generous support in helping to make MSIT a reality,” said Dennis S. Charney, the Anne and Joel Ehrenkranz Dean of Icahn School of Medicine at Mount Sinai and executive vice president for academic affairs at the Mount Sinai Medical Center. “The city has long recognized the need to expand applied science education and to establish research facilities for these efforts. The work that we’ll carry out at the Institute – from basic research to developing medical technology and devising effective treatments – will ultimately go a long way toward helping improve patient outcomes and the quality of life for people in New York City and beyond.”